7 recruiting. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Recruiting 7 |
| Phase 2 | 1 | Recruiting 1 |
Follow Emergencies: new trials by email Literature Review of Emergencies trials Research Report on Emergencies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Morphine or Ketamine for Analgesia Ketamine hydrochloride, Morphine sulphate - Abdominal Pain, Isolated Extremity Fracture | Phase 3 | Recruiting | Columbia University | 1010 | 2026-10-17 | 2026-10-20 |
| Emergency Department-Initiated Medications for Alcohol Use Disorder Naltrexone Pill, Naltrexone Injection, Brief Negotiation Interview - Alcohol Use Disorder | Phase 3 | Recruiting | Yale University | 240 | 2024-08-17 | 2026-07-21 |
| RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing Rivaroxaban 10 MG, Low Heparin Molecular Weight - Venous Thromboembolism, Deep Vein Thrombosis | Phase 3 | Recruiting | University Hospital, Angers | 1424 | 2024-07-19 | 2026-06-25 |
| Intravenous Ketorolac Vs. Morphine In Children With Acute Abdominal Pain Ketorolac Tromethamine, Morphine Sulfate, normal saline - Acute Pain, Abdomen, Acute | Phase 3 | Recruiting | University of Calgary | 495 | 2024-05-27 | 2024-06-24 |
| Early Initiated Vasopressor Therapy in the Emergency Department Noradrenaline - Shock, Shock, Septic | Phase 3 | Recruiting | Odense University Hospital | 320 | 2023-12-08 | 2025-07-01 |
| Ketamine & Crisis Response Plan for Suicidal Ideation in the ED Ketamine Hydrochloride, Crisis Response Plan - Suicide | Phase 2 / Phase 3 | Recruiting | The University of Texas Health Science Center at San Antonio | 24 | 2023-01-06 | 2026-09-30 |
| IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric], Ferrous Sulfate 65 mg elemental iron (325 mg tablets) - Anemia, Iron Deficiency, Uterine Bleeding | Phase 3 | Recruiting | Baylor College of Medicine | 40 | 2022-09-15 | 2024-12-05 |
Abdominal Pain (2) · Abdomen, Acute (1) · Acute Pain (1) · Agnosia (1) · Alcoholism (1) · Anemia, Iron-Deficiency (1) · Anxiety Disorders (1) · Appendicitis (1) · Depression (1) · Fractures, Bone (1) · Hypotension (1) · Hypovolemia (1) · Pain (1) · Pulmonary Embolism (1)
Disease Attributes (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Behavior (2) · Behavioral Symptoms (2) · Cardiovascular Diseases (2) · Infections (2) · Mental Disorders (2) · Neurologic Manifestations (2) · Signs and Symptoms (2) · Signs and Symptoms, Digestive (2) · Vascular Diseases (2) · Alcohol-Related Disorders (1) · Anemia (1) · Anemia, Hypochromic (1)
Ketamine (2) · Morphine (2) · Dalteparin (1) · Gabapentin (1) · Ketorolac Tromethamine (1) · Naltrexone (1) · Norepinephrine (1) · Rivaroxaban (1) · Saline Solution (1) · ferric derisomaltose (1) · ferrous sulfate (1)
Baylor College of Medicine (1) · Columbia University (1) · Odense University Hospital (1) · The University of Texas Health Science Center at San Antonio (1) · University Hospital, Angers (1) · University of Calgary (1) · Yale University (1)
United States (4) · Canada (1) · Denmark (1) · France (1) · Sweden (1)
Alan Peterson, PhD, ABPP (1) · Amy L Drendel, DO, MS (1) · Daniel S Tsze, MD, MPH (1) · Delphine Douillet, Doctor (1) · Kathryn Hawk, MD, MHS (1) · Lasse P Bentsen, MD (1) · Mikkel Brabrand, MD, PhD (1) · Mohamed Eltorki, MBChB (1) · Robert De Lorenzo, MD, MSM (1) · Romeo Fairley, MD, MPH (1) · Stacey Young-McCaughan, RN, PhD (1)
2023 (2), R01AA030568 (1), U01HD116253 (1), UL1TR002645 (1)